Company to Webcast Presentation on September 10
LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 27, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the company will be presenting at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10, 2007 at 11:30 AM (ET) at The Grand Hyatt New York.
At the conference, President and CEO Safi Bahcall, Ph.D. will discuss the company's oncology and inflammation drug discovery and development programs. A live audio webcast and replay of the presentation will be available on the "Investors" section of the company's website, www.syntapharma.com.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. For more information, please see www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
CONTACT: Synta Pharmaceuticals Corp. Rob Kloppenburg, 781-541-7125 or MacDougall Biomedical Communications Doug MacDougall, 508-647-0209 SOURCE: Synta Pharmaceuticals Corp.